[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100136805":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":44,"centralContacts":29,"locations":48,"responsibleParty":55,"collaborators":29,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":29,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":29,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":83,"whyStopped":29,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","PLACEBO_COMPARATOR","PF-00868554 (filibuvir) 100 mg or placebo",[13,14],"Drug: Active","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Cohort 2","PF-00868554 (filibuvir) 300 mg or placebo",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Cohort 3","PF-00868554 (filibuvir) 500 mg or placebo",[13,14],[24,30,34,37,39,42],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Active","Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.",[9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Placebo","Two subjects will receive the placebo under fasting condition.",[9],{"type":25,"name":26,"description":35,"armGroupLabels":36,"otherNames":29},"Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.",[16],{"type":25,"name":31,"description":32,"armGroupLabels":38,"otherNames":29},[16],{"type":25,"name":26,"description":40,"armGroupLabels":41,"otherNames":29},"Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.",[20],{"type":25,"name":31,"description":32,"armGroupLabels":43,"otherNames":29},[20],[45],{"name":46,"affiliation":5,"role":47},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[49],{"facility":50,"status":29,"city":51,"state":52,"zip":29,"country":53,"countryCode":54,"cosmosGeoPoint":29,"geoPoint":29,"contacts":29},"Pfizer Investigational Site","Shinjuku-ku","Tokyo","Japan","JP",{"type":29,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":56,"oldOrganization":57},"Director, Clinical Trial Disclosure Group","Pfizer, Inc.","100136805","phase-1-a-study-to-investigate-safety-and-pharmacokinetics-of-a-single-dose-of-pf-00868554-filibuvir-in-japanese-healthy-adult-volunteers-100136805",false,"NCT01051232","A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers","A Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 (Filibuvir) Following Single Oral Administrations Of PF-00868554 (Filibuvir) Under Fasting Conditions In Japanese Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy male and female subjects between the ages of 20 and 55 years.\n* Body Mass Index (BMI) of 17.5 to 30.5 kg\u002Fm2; and a total body weight \\>50 kg.\n\nExclusion Criteria:\n\n* A positive result for Hepatitis B surface antigen (HbsAg) or anti-hepatitis C virus serology, and HIV antigen\u002Fantibody.\n* Male subjects with a history of subfertility\u002Finfertility and other conditions that in the opinion of the investigator may affect fertility.\n* Pregnant or nursing females; females of childbearing potential.",true,"ALL","20 Years","55 Years",{"count":70,"type":71},24,"ACTUAL","INTERVENTIONAL",[74],"PHASE1","A single dose of PF-00868554 (filibuvir) will be safety and tolerable in Japanese healthy volunteers. The pharmacokinetics in Japanese will be consistent to that available in Western population.",[77],"Healthy",[79,80,81,82],"filibuvir","pharmacokinetics","Japanese","Asian","COMPLETED","2010-04-22",{"date":86,"type":87},"2010-04-26","ESTIMATED",{"date":89,"type":29},"2010-02",{"date":91,"type":71},"2010-04",{"name":5,"class":6},1]